Observational studyEuropean journal of nuclear medicine and molecular imaging2015
Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients.
Observational study in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis.Translational psychiatry · 2024Pooled it
- Structural and functional brain alterations in depression with Alzheimer's disease and mild cognitive impairment: a multimodal coordinate-based meta-analysis.Frontiers in aging neuroscience · 2026Review
- GWAS links APOE to neuropsychiatric symptoms in mild cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Anxious-depressive symptoms and sleep disturbances across the Alzheimer disease spectrum.Nature. Mental health · 2025Article
- Comprehensive Clinical and Behavioral Characteristics of Mild Cognitive Impairment According to Amyloid Positivity: A Large Multi-Center Korean Cohort.Dementia and neurocognitive disorders · 2025Article
- Subclinical depressive symptoms and job stress differentially impact memory in working and retired older adults.Scientific reports · 2025Article
- The role of elevated depressive symptoms in the incident mild cognitive impairment in China: a 9-year prospective cohort study of middle-aged and older Chinese adults (2011-2020).Frontiers in psychiatry · 2025Article
- Anti-Amyloid Drugs for Alzheimer's Disease: Considering the Role of Depression.Neuro-degenerative diseases · 2025Article
- Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology.Alzheimer's research & therapy · 2024Article
- Gut microbiome predicts cognitive function and depressive symptoms in late life.Molecular psychiatry · 2024Article
- Risk factors for cognitive decline in non-demented elders with amyloid-beta positivity.Alzheimer's research & therapy · 2024Article
- The interrelationships of CSF sTREM2, AD pathology, minimal depressive symptoms, and cognition in non-demented adults.Alzheimer's research & therapy · 2024Article
- Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.Journal of neurology · 2024Article
- Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Impact of transcutaneous vagus nerve stimulation on healthy cognitive and brain aging.Frontiers in neuroscience · 2023Review
- Depressive Pseudodementia with Reversible AD-like Brain Hypometabolism: A Case Report and a Review of the Literature.Journal of personalized medicine · 2022Article
- Mechanisms of Cognitive Impairment in Depression. May Probiotics Help?Frontiers in psychiatry · 2022Review
- Relationship among number of close friends, subclinical geriatric depression, and subjective cognitive decline based on regional homogeneity of functional magnetic resonance imaging data.Frontiers in aging neuroscience · 2022Article
- Common mental disorders during the COVID-19 pandemic in Hong Kong: Age-related differences and implications for dementia risk.Frontiers in psychiatry · 2022Article
- Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum.Frontiers in aging neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeLate-life depression even in subsyndromal stages is strongly associated with Alzheimer's disease (AD). Furthermore, brain amyloidosis is an early biomarker in subjects who subsequently suffer from AD and can be sensitively detected by amyloid PET. Therefore, we aimed to compare amyloid load and glucose metabolism in subsyndromally depressed subjects with mild cognitive impairment (MCI).
methods[(18)F]AV45 PET, [(18)F]FDG PET and MRI were performed in 371 MCI subjects from the Alzheimer's Disease Neuroimaging Initiative Subjects were judged β-amyloid-positive (Aβ+; 206 patients) or β-amyloid-negative (Aβ-; 165 patients) according to [(18)F]AV45 PET. Depressive symptoms were assessed by the Neuropsychiatric Inventory Questionnaire depression item 4. Subjects with depressive symptoms (65 Aβ+, 41 Aβ-) were compared with their nondepressed counterparts. Conversion rates to AD were analysed (mean follow-up time 21.5 ± 9.1 months) with regard to coexisting depressive symptoms and brain amyloid load.
resultsAβ+ depressed subjects showed large clusters with a higher amyloid load in the frontotemporal and insular cortices (p < 0.001) with coincident hypermetabolism (p < 0.001) in the frontal cortices than nondepressed subjects. Faster progression to AD was observed in subjects with depressive symptoms (p < 0.005) and in Aβ+ subjects (p < 0.001). Coincident depressive symptoms additionally shortened the conversion time in all Aβ+ subjects (p < 0.005) and to a greater extent in those with a high amyloid load (p < 0.001).
conclusionOur results clearly indicate that Aβ+ MCI subjects with depressive symptoms have an elevated amyloid load together with relative hypermetabolism of connected brain areas compared with cognitively matched nondepressed individuals. MCI subjects with high amyloid load and coexistent depressive symptoms are at high risk of faster conversion to AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.